Does NIH comply with 40 USC 559, and consult Department of Justice when issuing exclusive patent licenses? Apparently not.
Government Funded research
KEI Comments Regarding NIH Exclusive License to PreciThera
(Update: The NIH provided a response to our comments on August 24, 2020) On August 20, 2020, Knowledge Ecology International (KEI) submitted comments regarding the prospective grant of an exclusive license by the National Institutes of Health (NIH) to PreciThera,… Continue Reading
KEI and UACT Comments Regarding NIH Exclusive License to Cytovia for CAR Technology
On August 14, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the NIH’s “Prospective Grant of an Exclusive Patent License: Allogeneic Therapy Using Chimeric Antigen Receptors Targeting GPC3” (85 FR 45912). The… Continue Reading
Italy undertakes bold measures on transparency by adopting the Pricing and Reimbursement Decree
On Friday, 24 July 2020, Italy officially published the long-anticipated Pricing and Reimbursement Decree in the Gazzetta Ufficiale della Repubblica Italiana setting in motion Italy’s place as the first country to implement the WHO transparency resolution (WHA72.8). In statement before… Continue Reading
WTO TRIPS Council (July 2020): The European Union’s position on the interface of IP and health technologies in the COVID-19 response
On 30 July 2020, the World Trade Organization (WTO) convened a formal meeting of the TRIPS Council. The TRIPS Council held discussions on two COVID-19 related topics: agenda item 3 on IP Measures in the Context of COVID-19 and agenda… Continue Reading
BARDA Responds to KEI, Public Citizen Letter Asking BARDA to Enforce Moderna Contract
(More on Moderna here: https://www.keionline.org/moderna) On August 5, 2020, BARDA Acting Director Gary Disbrow sent KEI and Public Citizen a letter (PDF copy) responding to KEI and Public Citizen’s joint letter outlining how Moderna failed to honor a term of… Continue Reading
KEI and Public Citizen request BARDA to address Moderna’s noncompliance with COVID-19 vaccine contract term
(More on Moderna here: https://www.keionline.org/moderna) On July 31, 2020, Knowledge Ecology International and Public Citizen sent Biomedical Advanced Research and Development Authority (BARDA) a letter asking BARDA to enforce a term of Moderna’s billion dollar contract with BARDA to develop… Continue Reading
Joint letter to Dr. Fauci at NIAID, regarding the geographic scope of RNAceuticals HIV patent license, asks that exclusivity not extend to countries with low and moderate incomes
Below is a letter from several individuals and groups, asking that NIAID not grant exclusive rights in a HIV patent license for South Africa, India and other low income countries. (PDF version here) The license is to RNAceuticals, a firm… Continue Reading
KEI Comments Regarding NIH Exclusive License to RNAceuticals for Anti-HIV Antibodies
On July 27, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent Commercialization License: N6, a Novel, Broad, Highly Potent HIV-Specific Antibody and a Broadly Neutralizing Human Anti-HIV… Continue Reading
KEI Comments Regarding NIH Exclusive License to Paz Pharmaceuticals for Cancer Treatment
On July 7, 2020, Knowledge Ecology International (KEI) submitted comments to the Federal Register notice for the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fenoterol and Certain Fenoterol Analogues for the… Continue Reading